Protein kinase CK2: a potential therapeutic target for diverse human diseases
Autor: | Stefania Sarno, Christian Borgo, Claudio D'Amore, Maria Ruzzene, Mauro Salvi |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
Cancer Research animal structures Cystic Fibrosis Eye Diseases QH301-705.5 Inflammation Medicinal chemistry Drug development Review Article Bioinformatics medicine.disease_cause Virus 03 medical and health sciences 0302 clinical medicine Target identification Genetics Medicine Humans Phosphorylation Biology (General) Protein kinase A Casein Kinase II Protein Kinase Inhibitors Mutation business.industry SARS-CoV-2 Mental Disorders fungi Cancer COVID-19 medicine.disease COVID-19 Drug Treatment 030104 developmental biology Cardiovascular Diseases 030220 oncology & carcinogenesis embryonic structures medicine.symptom Casein kinase 2 Signal transduction business Signal Transduction |
Zdroj: | Signal Transduction and Targeted Therapy, Vol 6, Iss 1, Pp 1-20 (2021) Signal Transduction and Targeted Therapy |
ISSN: | 2059-3635 |
Popis: | CK2 is a constitutively active Ser/Thr protein kinase, which phosphorylates hundreds of substrates, controls several signaling pathways, and is implicated in a plethora of human diseases. Its best documented role is in cancer, where it regulates practically all malignant hallmarks. Other well-known functions of CK2 are in human infections; in particular, several viruses exploit host cell CK2 for their life cycle. Very recently, also SARS-CoV-2, the virus responsible for the COVID-19 pandemic, has been found to enhance CK2 activity and to induce the phosphorylation of several CK2 substrates (either viral and host proteins). CK2 is also considered an emerging target for neurological diseases, inflammation and autoimmune disorders, diverse ophthalmic pathologies, diabetes, and obesity. In addition, CK2 activity has been associated with cardiovascular diseases, as cardiac ischemia–reperfusion injury, atherosclerosis, and cardiac hypertrophy. The hypothesis of considering CK2 inhibition for cystic fibrosis therapies has been also entertained for many years. Moreover, psychiatric disorders and syndromes due to CK2 mutations have been recently identified. On these bases, CK2 is emerging as an increasingly attractive target in various fields of human medicine, with the advantage that several very specific and effective inhibitors are already available. Here, we review the literature on CK2 implication in different human pathologies and evaluate its potential as a pharmacological target in the light of the most recent findings. |
Databáze: | OpenAIRE |
Externí odkaz: |